Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
